Paris-based Sanofi will enter into a joint venture with the Swiss drug manufacturer Lonza to open a $285 million biologics facility by 2020, reports Reuters.
Lonza will construct and operate the facility in Visp, Switzerland, which will produce monoclonal antibodies for the use in biologic drugs. The company has previously set up similar sites in the U.S. and Singapore, according to the report.
"Approximately 60 percent of our pipeline is made up of biologics, including monoclonal antibodies, dedicated to key disease areas such as cardiovascular, immunology and inflammation, neurology and oncology," Philippe Luscan, executive vice president of global industrial affairs at Sanofi, said in a statement.
The deal is still pending regulatory approval. If approved, the new site will bring about 200 jobs to the area, according to a spokesman for Sanofi.
More articles on supply chain:
Why pharmacists can't speak up when they know customers are overpaying for drugs
LCMC Health partners with The Resource Group for supply chain services
Pharma leaders, healthcare experts advocate value-based payments for drugs